Date: Monday, October 22, 2018
Session Type: ACR Concurrent Abstract Session
Session Time: 2:30PM-4:00PM
Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice– pooled data from the EuroSpA Research Network Collaboration
A research network collaboration of 15 European registries sharing data on patients with spondyloarthritis (SpA), “EuroSpA”, has recently been created to strengthen research capabilities in the real world setting1.
We aimed to investigate Tumour Necrosis Factor inhibitor (TNFi) retention and response rates at 6, 12 and 24 months in patients with axial SpA (axSpA) treated with their 1st, 2nd or 3rd TNFi in clinical practice across Europe.
A common data model was agreed upon by the EuroSpA Scientific Committee. Registry data managers clarified data availability and uploaded anonymized data through the secure Virtual Private Network pipelines to the EuroSpA server. Baseline characteristics, drug retention and response rates after 6, 12 and 24 months were investigated with non-parametric descriptive statistics. Kaplan-Meier estimation was used to investigate TNFi retention rates. Both crude and Lundex adjusted2 response rates were calculated for BASDAI remission (BASDAI<4) and ASDAS inactive disease (ASDAS<1.3 unit).
In May 2018, 10 of the 15 registries participating in EuroSpA had completed data upload to the EuroSpA server, including 21,470 patients with axSpA. Baseline characteristics of the pooled population are shown in Table.
For the 1st TNFi, 6 and 24 months´ retention rates were 87% and 71%, respectively. Corresponding retention rates for the 2nd TNFi were 80% and 63%, and for the 3rd TNFi 81% and 62%, respectively (Table and Figure). For the 1st TNFi, 6 and 24 months Lundex adjusted BASDAI remission rates were 57% and 36%. Corresponding remission rates for the 2nd TNFi were 42% and 25%, and for the 3rd TNF, 36% and 20%. For the 1st TNFi, 6 and 24 months Lundex adjusted ASDAS inactive disease rates were 26% and 17%, respectively. Corresponding ASDAS inactive disease rates for the 2nd TNFi were 16% and 11%, and for 3rd TNFi, 12% and 6%.
These initial analyses demonstrate that the creation of a large European database of axSpA patients treated in routine care based on a common data model is feasible, offering important opportunities for future research. In this pooled dataset from 10 European registries, we found decreasing retention rates for the 2nd and 3rd TNFi compared to the 1st TNFi, and lower response rates with increasing number of previous TNFi.
References: 1) Ann Rheum Dis, 2017, suppl. 2, p. 65
References: 2) Arthritis Rheum, 2006, 54(2), p. 600-6.
To cite this abstract in AMA style:Brahe CH, Ørnbjerg LM, Askling J, Ciurea A, Kristianslund EK, Onen F, Nordström D, Santos MJ, Codreanu C, Rotar Z, Gudbjornsson B, Di Giuseppe D, Nissen MJ, Kvien T, Birlik M, Trokovic N, Barcelos A, Ionescu R, Tomšič M, Geirsson AJ, Loft AG, Mann HF, Rusman T, Gomez-Reino JJ, Jones GT, Iannone F, Pavelka K, van der Horst-Bruinsma I, Hyldstrup L, Krogh NS, Hetland ML, Østergaard M. Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/drug-retention-and-response-rates-of-tnfi-treatment-in-21470-patients-with-axial-spondyloarthritis-treated-in-clinical-practice-pooled-data-from-the-eurospa-research-network-collaboration/. Accessed June 15, 2021.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/drug-retention-and-response-rates-of-tnfi-treatment-in-21470-patients-with-axial-spondyloarthritis-treated-in-clinical-practice-pooled-data-from-the-eurospa-research-network-collaboration/